Company: DMAC
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001437749-25-026207
Chunk: 7

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 1
Chunk 7
---
 Plan (2021 Inducement Plan)
   The 2021 Inducement Plan permits the Board, or a committee or subcommittee thereof, to grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to new employees who satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. The Inducement Plan has a term of 10 years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board. As of June 30, 2025, options to purchase an aggregate of 590,000 common shares were outstanding under the Inducement Plan and 357,500 shares remained available for issuance.   Prior Stock Option Plan
   The Company’s prior stock option plan was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of June 30, 2025, options to purchase an aggregate of 374,410 common shares were outstanding.   Prior Deferred Stock Unit Plan
   The Company’s prior deferred stock unit plan was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of June 30, 2025, there were 9,745 common shares reserved for issuance upon settlement of DSUs outstanding.      11

  
  Share-based compensation expense for each of the periods presented is as follows (in thousands):    
                                             Three Months Ended                     Six Months Ended      
                                                  June 30,                              June 30,          
----------------------------------------------------------------------------------------------------------
                                 2025                  2024              2025                 2024        
General and administrative                $538                    $336          $1,216                $629
Research and development                   233                     107             422                 302
Total share-based compensation            $771                    $443          $1,638                $931
    We recognize share-based compensation for options awards based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those options that